People · Operator
Named in public records as an officer, director or promoter · active 2014–2018 · Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Curaleaf Holdings, Inc. | — | Other | Series D+ | $691.1M | $2.6B | 2018 |
| First Wave BioPharma, Inc. | — | Biotechnology | Series B | $50.4M | $13.4M | 2014 |
Christine Rigby at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christine Rigby on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mitchell Kahn | 1 | 7 |
| David Hoffman | 1 | 7 |
| James Sapirstein | 1 | 7 |
| Charles Casamento | 1 | 5 |
| Johan (Thijs) Spoor | 1 | 4 |
| Johan M Spoor | 1 | 3 |
| Sarah Romano | 1 | 3 |
| Maged Shenouda | 1 | 3 |
| Jack Syage | 1 | 2 |
| Ed Kremer | 1 | 2 |
| Richard Paolone | 1 | 2 |
| Eric Corbett | 1 | 2 |
| Steven Patierno | 1 | 2 |
| Boris Jordan | 1 | 2 |
| Daniel . Schneiderman | 1 | 2 |
| Chris Melillo | 1 | 2 |
| Jason Sawyer | 1 | 2 |
| Peter Clateman | 1 | 1 |
| Rahul Pinto | 1 | 1 |
| Joseph Lusardi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.